Bardzo tanie apteki z dostawą w całej Polsce kupic viagra i ogromny wybór pigułek.

The Organocatalysis is a fluent and vibrant new field of research which is introducing new methods and concepts in organic synthesis. Organocatalysis is the catalysis of chemical reactions with small organic molecules. A metal is typically not present in the substrate, nor is it a part of the catalytic mode of action. Traditionally, chemists use almost exclusively metal-containing catalysts. This is surprising if one considers that only half of the enzymes, the efficient catalysts of nature, contain metals.
Only recently, have chemists realized that even low molecular weight pure organic catalysts are able to catalyze chemical reactions in a highly efficient and selective manner. Such organocatalytic reactions are attractive not only from an academic point of view, but they are particularly useful for industrial syntheses: the catalysts used are typically robust, not expensive, nontoxic and easy to synthesize. Other advantages of organocatalytic reactions are that they are generally insensitive to air and moisture and are often carried out at room temperature.
Since the rediscovery of Organocatalysis by List, MacMillan, Barbas, Jørgensen, Terada, Akiyama, Hayashi and many others, the appeal of the new methodology has encountered the favor of the Chemical Community. The number of publications concerning organocatalytic methodologies has grown exponentially in the last decade. CATAFLU.OR Symposium
A symposium of organocatalysis will be organized in Bologna on 24-25 March 2011 to celebrate the success of organocatalysis and to present the results obtained in the context of the European project called CATAFLU.OR.
During the symposium, all aspects of organocatalysis related to new reactions, new organocatalytic cascade processes, new mechanistic studies of organocatalytic Despite widespread immunization, influenza still kills thousands of people, and costs to the US, Europe and Asia enormous amounts of money in terms of healthcare expenses and productivity losses. Small-molecule antiviral agents represent a novel opportunity for an effective prevention and therapy of flu. Inhibitors of neuraminidase (NA), essential enzymes for viral replication in all three classes of influenza viruses, March, 24/25 - 2011
have been recently found. Two of these inhibitors have reached the market, namely Hotel Re Enzo,
zanamivir and oseltamivir phosphate. The recent health concerns related to the avian Via Santa Croce 26
flu have increased the demand for stockpiles of neuraminidase inhibitors, both as a Bologna - Italy
reasonable frontline therapy against a possible flu pandemic and as a preventive agent. In order to find new drug candidates, cut the drug costs and improve availability as well as efficiency, new chemical syntheses are necessary. The project proposes a new domino reaction based on an organocatalytic approach to the synthesis of Tamiflu and new inhibitors of neuraminidase derivatives.
Professor Pier Giorgio Cozzi, University of Bologna Thursday 24th
Friday 25th
09.15 Introduction and welcome
09.00 Kinetic Aspects of Nucleophilic Organocatalysis
PG. Cozzi, F. Zerbetto, University of Bologna 09.30 Aminocyclohexenes - From an unwanted side product to a
09.40 Asymmetric organocatalysis under non-traditional conditions
versatile synthetic platform
10.10 Catalysis and Cascades in Complex Alkaloid Natural
10.00 New Concepts in Organocatalysis
Product Synthesis’
10.40 New indole derived organocatalysts and their applications in
asymmetric Michael reactions
11.20 Characterization of Reactive Intermediates
in Organocatalysis - generally accepted mechanisms
revisited and revised
11.30 Organocatalysis under less common conditions
12.00 Selected communication chaired by P.G Cozzi
Organocatalysis with Weak Interactions: Cooperativity and Bifunctionality 12.10 Selected communication chaired by PG. Cozzi
are Essential for Stereocontrol - Luca Bernardi, University of Bologna New Strategies in Organocatalysis: Enamines and (Chiral) Bases - Marco Bella, Cooperative Combination of Enantioselective Organocatalysis with Purely Organic, Visible Light Photoredox Catalysis - Kirsten Zeitler, University of Catalytic Asymmetric Epoxidation of α-Branched Enals - Olga Lifchits, Max- 14.00 Design of High-Performance Organocatalysts for
14.30 Two “One-Pot” synthesis of Tamiflu and Organocatalysis
Green Sustainable Chemistry
15.10 Cinchona-based Primary Amines: Toward the
14.40 Asymmetric Catalysis with Peptides and Other Bioinspired
Second Generation of Privileged Organocatalysts
P. Melchiorre, Institute of Chemical Research of Catalonia (ICIQ) 15.50 Chiral Ion Pair Catalysis - From Biologically Inspired
15.20 Organocatalytic asymmetric conjugate addition of
Concepts to Applications
carbonyl compounds to Michael acceptors
17.00 Selected Communication chaired by P.G. Cozzi
16.30 Selected Communication chaired by P.G. Cozzi
Enamine intermediates in aminocatalysis: Detection and Characterization - Desymmetrization of meso-Aziridines with Chalcogen-centered Nucleophiles Catalyzed by VAPOL-hydrogen Phosphate - Giorgio Dalla Sala, University of Enantioselective Reduction of Carbon-nitrogen Double Bond - Ethynyl BeziodoXolone (EBX) as Reagent for Metal-free Ethynylation of Stable SN1-type reactions in the Presence of Water: Indium (III) Promoted Highly - Davinia Fernandez, Polytechnic of Lausanne Enantioselective Organocatalytic Propargylation of Aldehydes - Andrea Gualandi, New Organocatalytic Process Involving Michael type Additions - Jose Aleman, Thiourea-Cinchona Alkaloid-Catalyzed Asimmetric Addition of β-ketosulfonate to Green, Enviromentally Sustainable Organocatalysis Using Bifunctional Nitroalkenes: an Easy Acess to Functionalyzed Chiral Cyclic Nitrones - Olga Garcia, Aminoboronic Acids: Applications for the Synthesis of Bioactive Piperidine Alkaloid Derivatives - Irene Georgiou, University of Durham


Ct-5267 xyzall

COMMISSION DE LA TRANSPARENCE Examen du dossier de la spécialité inscrite pour une durée de 5 ans par arrêté du 9 avril 2003 (JO du 11 avril 2003) XYZALL 5 mg, comprimé pelliculé Boîte de 14 comprimés (CIP : 358 502-4) Boîte de 28 comprimés (CIP : 358 505-3) Laboratoires UCB PHARMA SA Lévocétirizine Date de l'AMM : 14 février 2002 (procédure de reconnaissance

EUROBOSQUES, S.L. CUENTAS CERRADAS A 31 DE DICIEMBRE DE 2.011 CORRESPÒNDIENTES A L BALANCE DE SITUACION EUROBOSQUES, S.l. EJERCICIO 2011 A) ACTIVO NO CORRIENTE 125.514,09 I. Inmovilizado intangible 125.514,09 6. Investigación 122.514,09 2800. Amortización acumulada de investigación 7. Otro inmovilizado intangible 3.000,00 3.000,00 209. Anticipos para

Copyright © 2010-2014 Medical Articles